In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines

Oncology Reports

Volumn 11, Issue 2, 2004, Pages 407-414

  Loprevite, Maura ^a   Favoni, Roberto E ^a   De Cupis, Alessandra ^a   Scolaro, Tindaro ^a   Semino, Claudia ^b   Mazzanti, Paola ^c   Ardizzoni, Andrea ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Advanced Biotechnology Center   (Italy)

^c Centro Direzionale Milano 2   (Italy)

Author keywords

Combined therapy; K ras; Pre clinical investigation; Pulmonary neoplasia

Indexed keywords

ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; LONAFARNIB; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TRANSFERASE;

ARTICLE; DRUG ANTAGONISM; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; TUMOR CELL LINE;

ALKYL AND ARYL TRANSFERASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LUNG NEOPLASMS; PIPERIDINES; PYRIDINES;

EID: 3242803823     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.2.407     Document Type: Article

References (40)

1. Bos JL: The ras family and human carcinogenesis. Mutat Res 195: 255-271, 1988.
2. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
3. Clarke S: Protein isoprenylation and methylation at carboxylterminal cysteine residues. Ann Rev Biochem 61: 355-386, 1992.
4. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ: Isoprenoid addition to ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403, 1992.
5. Prendergast GC: Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. Curr Opin Cell Biol 12: 166-173, 2000.
6. Lebowitz PF, Casey PJ, Prendergast GC and Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272: 15591-15594, 1997. (Pubitemid 27265524)
7. Lebowitz PF and Prendergast GC: Non-ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17: 1439-1445, 1998. (Pubitemid 28458411)
8. Adjei AA, Davis JN, Bruzek LM, Erlichman C and Kaufmann SH: Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7: 1438-1445, 2001. (Pubitemid 32708700)
9. Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M and Nielsen LL: The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 46: 387-393, 2000.
10. Rowinsky EK, Windle JJ and von Hoff DD: Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development. J Clin Oncol 17: 3631-3652, 1999. (Pubitemid 29517936)
11. Kohl NE, Wilson FR, Mosser SD, Giuliani E, De Solms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB and Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141, 1994.
12. Sun J, Quian Y, Hamilton AD and Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumour growth in nude mice in a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995.
13. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge GF, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Kirschmeier P and Bishop WR: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res 58: 4947-4956, 1998. (Pubitemid 28503695)
14. Loprevite M, Varesco L, Favoni R, Ferrara GB, Moro F, Ottaggio L, Fronza G, Campomenosi P, Abbondandolo A, Cutrona G, Roncella S, Albini A, Aluigi MG, Pozzi S, Pera C, Biticchi R, Gismondi V, Grossi F, Pennucci MC and Ardizzoni A: Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. Int J Oncol 11: 1203-1208, 1997. (Pubitemid 27502072)
15. Carmichael J, De Graff WJ, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
16. Webb JL: Effect of more than one inhibitor. In: Enzymes and Metabolic Inhibitors, volume 1. Academic Press, NY, p66, 1963.
17. Kern DH, Morgan CR and Hildebrand-Zanki SU: In vitro pharmacodynamics of 1-beta-D-arabinofuranosylcytosine: synergy of antitumor activity with diaminedichloroplatinum(II). Cancer Res 48: 117-121, 1988. (Pubitemid 18030339)
18. Eskens FALM, Stoter G and Verweij J: Farnesyl transferase inhibitors. Current developments and future perspectives. Cancer Treat Rev 26: 319-332, 2000.
19. Gibbs JB, Oliff A and Kohl NE: Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 77: 175-178, 1994. (Pubitemid 24138615)
20. Crespo NC, Ohkanda J, Yen T, Hamilton AD and Sebti SM: The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276: 16161-16167, 2001.
21. Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Cooper AB, Rane DF, Liu YT, Wong J, Vibulbhan B, Pinto P, Deskus J, Alvarez CS, Del Rosario J, Connolly M, Wang J, Desai J, Rossman RR, Bishop WR, Patton R, Wang L, Kirschmeier P and Ganguly AK: (+)-4-[2-[4-(8-Chloro-3,10- dibromo-6,11-dihydro5Hbenzo[5,6]cycloheptal (1,2-b]-pyridin-]((R)-yl)-1- piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH 66336) a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem 41: 4890-4902, 1998. (Pubitemid 28530464)
22. Karp JE, Kauffmann SH, Adjei AA, Lancet JE, Wright JJ and End DW: Current status of clinical trials of farnesyl transferase inhibitors. Curr Opin Oncol 13: 470-476, 2001. (Pubitemid 33027899)
23. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD and Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res 55: 5310-5314, 1995.
24. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A and Rosen N: A peptidomimetic inhibitor of farnesylprotein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res 55: 5302-5309, 1995.
25. Petit T, Izbicka E, Lawrence RA, Bishop WR, Weitman S and von Hoff DD: Activity of SCH66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Ann Oncol 10: 449-453, 1999. (Pubitemid 29236423)
26. James GL, Goldstein JL and Brown MS: Resistance of K-rasBV12 proteins to farnesyltransferase inhibitors in Rat1 cells. J Biol Chem 270: 6221-6226, 1995.
27. Rowell CA, Kowalczyk JJ, Lewis MD and Garcia AM: Direct demonstration of geranylgeranylation and farnesylation of Ki-ras in vivo. J Biol Chem 273: 20243-20251, 1997.
28. Ashar HR, James L, Gray K, Carr D, McGuirk M, Maxwell E, Black S, Armstrong L, Doll RJ, Taveras AG, Bishop WR and Kirshmeier P: The farnesyl transferase inhibitor SCH 66336 induces a G2→M or G1 pause in sensitive human tumor cell lines. Exp Cell Res 262: 17-27, 2001. (Pubitemid 32989004)
29. Sepp-Lorenzino L and Rosen N: A farnesyl-protein transferase inhibitor induces p21Cip1 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273: 20243-20251, 1998. (Pubitemid 28377586)
30. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su D, Danishefsky SJ and Rosen N: Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 95: 1369-1374, 1998. (Pubitemid 28103398)
31. Sun J, Blaskovich MA and Knowles D: Antitumor efficacy of a novel class of non-Thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine. Cancer Res 59: 4919-4926, 1999. (Pubitemid 29472897)
32. Prévost GP, Pradines A, Brezak M-C, Lonchampt M-O, Viossat I, Ader I, Toulas C, Kasprzyk P, Gordon T, Favre G and Morgan B: Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. Int J Cancer 91: 718-722, 2001. (Pubitemid 32115270)
33. Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu JM and Bernhard EJ: The farnesyltransferase inhibitor L774,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61: 2289-2293, 2001. (Pubitemid 32692061)
34. Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P and Kaufmann SH: A phase I trial of the farnesyltransferase inhibitor SCH 66336: evidence for biological and clinical activity. Cancer Res 60: 1871-1877, 2000. (Pubitemid 30207646)
35. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Belly CRT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB and Cowan KH: Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18: 927-941, 2000. (Pubitemid 30106625)
36. Johnston SRD: Farnesyltransferase inhibitors: a novel targeted therapy for cancer. Lancet Oncol 2: 18-26, 2001.
37. Sebti SM and Hamilton AD: Farnesyltransferase and geranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. Exp Opin Investig Drugs 9: 2767-2782, 2000.
38. Eskens FALM, Awada A, Cutler DL, De Jonge MJ, Luyten GP, Faber MN, Statkenich P, Sparreboom A, Verweij J, Hananske AR and Piccart M: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19: 1167-1175, 2001. (Pubitemid 32176295)
39. Awada A, Eskens F, Piccart MJ, van der Gaast A, Bleiberg H, Cutler DL, Fumoleau P, Wanders J, Faber MN and Verweij J: A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH) an oral inhibitor of the enzyme farnesyltransferase given once daily in patients with solid tumors. Clin Cancer Res 5: S3733, 1999.
40. Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erlichman C, Kaufmann SH and Vokes EE: Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 1760-1766, 2003. (Pubitemid 46638589)